B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy
Bruce E. Johnson,John P. Chute,Jeanne M. Rushin,John A. Williams,Phuong Tram Le,David Venzon,Gary Richardson +6 more
TL;DR: AVP appears to be elevated in nearly all patients with hyponatremia of malignancy and atrial natriuretic peptide plasma levels in patients with lung cancer are associated with the ability to excrete a sodium load but do not appear to downregulate renin, angiotensin II, and aldosterone production.
Journal ArticleDOI
Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer
Curtis R. Chong,Magda Bahcall,Marzia Capelletti,T. Kosaka,Dalia Ercan,Taebo Sim,Taebo Sim,Lynette M. Sholl,Mizuki Nishino,Bruce E. Johnson,Nathanael S. Gray,Pasi A. Jänne +11 more
TL;DR: This study highlights that existing agents may be repurposed to overcome drug resistance and identifies cabozantinib as a promising treatment of ROS1-rearranged NSCLC after progression on crizotinib.
Journal ArticleDOI
Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics
TL;DR: This article synthesizes the opinions and issues considered at the American Association for Cancer Research Clinical and Translational Cancer Research Think Tank meeting held in San Francisco in early 2010, and discusses many of the important events that have since occurred in the field of personalized cancer medicine.
Journal ArticleDOI
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
Lambros Zellos,William G. Richards,Leah Capalbo,Michael T. Jaklitsch,Lucian R. Chirieac,Bruce E. Johnson,Bruce E. Johnson,Raphael Bueno,David J. Sugarbaker +8 more
TL;DR: Early stage and negative extrapleural lymph nodes were associated with prolonged survival and single-dose amifostine did not protect adequately against cisplatin-induced renal toxicity.
Journal ArticleDOI
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Conor E. Steuer,Madhusmita Behera,Lynne D. Berry,Sungjin Kim,Michael R. Rossi,Gabriel Sica,Taofeek K. Owonikoko,Bruce E. Johnson,Mark G. Kris,Paul A. Bunn,Fadlo R. Khuri,Edward B. Garon,Suresh S. Ramalingam +12 more
TL;DR: The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population.